Long Ideas - Synergy’s equity financing, which wrapped up last Tuesday, put the company in a strong position for a partnership (or M&A) negotiation regarding plecanatide. The stock … Continue Reading
Read nowLong Ideas - ICPT has a big problem, and could be headed back to its post-IPO prices, 50% lower than where they trade today. The company piqued our … Continue Reading
Read nowMost Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read nowLong Ideas - Although Illumina was slapped with a $96M fine by a federal jury this week, the monetary penalty isn’t all that detrimental to the $6B company; … Continue Reading
Read nowLong Ideas - Keryx Biopharmaceuticals’ (KERX) CEO, Ron Bentsur, spent much of the company’s 4Q/YE12 earnings conference call reviewing patents, pending patents, and potential exclusivity designations for Zerenex, … Continue Reading
Read nowMost Popular - IMUC proved a successful trade in the short-term, climbing 34% since our report was published on the first of the month. In early trials, lead … Continue Reading
Read nowLong Ideas - The spin doctors have done a great job pressuring Keryx BioPharmaceuticals (KERX) recently, pulling out all the stops to drive the stock down. Massive share … Continue Reading
Read now